These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11728139)

  • 1. Caeteris paribus - all things being equal.
    Giugliano RP; Antman EM
    Eur Heart J; 2001 Dec; 22(24):2221-3. PubMed ID: 11728139
    [No Abstract]   [Full Text] [Related]  

  • 2. Life after DIAS II.
    Donnan GA; Davis SM
    Int J Stroke; 2007 Nov; 2(4):236-7. PubMed ID: 18705921
    [No Abstract]   [Full Text] [Related]  

  • 3. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 4. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy.
    Zacharski LR; Donati MB
    Thromb Haemost; 1989 Jun; 61(3):526-8. PubMed ID: 2799765
    [No Abstract]   [Full Text] [Related]  

  • 5. Urokinase: new indication. Thrombosed venous and dialysis catheters: when heparin fails. Urokinase clears about 75% of thrombosed venous catheters intended for long-term use with a dose-related increase in the bleeding risk.
    Prescrire Int; 2009 Jun; 18(101):118. PubMed ID: 19637430
    [No Abstract]   [Full Text] [Related]  

  • 6. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: a meta-analysis of contemporary randomized controlled trials.
    Wijeysundera HC; You JJ; Nallamothu BK; Krumholz HM; Cantor WJ; Ko DT
    Am Heart J; 2008 Sep; 156(3):564-572, 572.e1-2. PubMed ID: 18760142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter-directed thrombolysis for the treatment of symptomatic deep vein thrombosis.
    Grunwald MR; Hofmann LV
    Circulation; 2004 Jan; 109(2):e10; author reply e10. PubMed ID: 14734512
    [No Abstract]   [Full Text] [Related]  

  • 11. On "Current role of antithrombotic agents in the treatment of acute coronary syndromes" (Semin Thromb Hemost 2004;30:627-632).
    Nessel CO
    Semin Thromb Hemost; 2005 Apr; 31(2):248. PubMed ID: 15852228
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants.
    Büller HR; Halperin JL; Bounameaux H; Prins M
    J Thromb Haemost; 2008 Feb; 6(2):227-9. PubMed ID: 18034770
    [No Abstract]   [Full Text] [Related]  

  • 13. Meta-analysis finds angioplasty more effective than thrombolytic therapy in treating heart attack.
    Rollins G
    Rep Med Guidel Outcomes Res; 2003 Jan; 14(2):1-2, 5. PubMed ID: 12776698
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic thrombolysis in clinical practice: what have we learned after the Safe Implementation of Thrombolysis in Stroke Monitoring Study?
    Wahlgren N
    Cerebrovasc Dis; 2009; 27 Suppl 1():168-76. PubMed ID: 19342848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital].
    Takahashi K; Iijima K; Oguro H; Bokura H; Nagai A; Yamaguchi S; Kobayashi S
    No To Shinkei; 2005 Aug; 57(8):683-8. PubMed ID: 16146212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic therapy for acute pulmonary embolism.
    Sharma G; Kothari SS; Bahl VK
    Indian Heart J; 2002; 54(6):667-71. PubMed ID: 12674177
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction.
    Antman EM; Van de Werf F
    Circulation; 2004 Jun; 109(21):2480-6. PubMed ID: 15173037
    [No Abstract]   [Full Text] [Related]  

  • 18. Life after SAINT.
    Hallevi H; Aronowski J
    Int J Stroke; 2007 Nov; 2(4):241-2. PubMed ID: 18705923
    [No Abstract]   [Full Text] [Related]  

  • 19. ASSENT-3: implications for future trial design and clinical practice.
    Van de Werf F
    Eur Heart J; 2002 Jun; 23(12):911-2. PubMed ID: 12069439
    [No Abstract]   [Full Text] [Related]  

  • 20. Intra-arterial thrombolysis in acute ischemic stroke: a review of pharmacologic approaches.
    Pettersen JA; Hudon ME; Hill MD
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):285-99. PubMed ID: 15151476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.